Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1935 studies found for:    Farber's Disease
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Biomarker for Farber Disease
Conditions: Farber's Lipogranulomatosis;   Ceramidase Deficiency;   Farber Disease;   Acid Ceramidase Deficiency;   AC Deficiency
Intervention:
2 Completed Mantle Irradiation for Hodgkin's Disease
Condition: Hodgkin's Disease
Intervention: Procedure: Mantle irradiation
3 Recruiting A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host-disease
Interventions: Procedure: Extracorporeal Photopheresis (ECP);   Drug: Interleukin-2
4 Active, not recruiting Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
Condition: Hodgkin's Disease
Intervention: Procedure: Echo/Stress Echo
5 Recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
6 Completed Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease
Conditions: Breast Cancer;   Hodgkin's Disease
Interventions: Procedure: breast MRI;   Procedure: Mammogram
7 Active, not recruiting
Has Results
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Condition: Lung Cancer
Intervention: Procedure: chest computed tomography scan
8 Recruiting Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Versus Graft Host Disease
Intervention: Drug: Interleukin-2
9 Not yet recruiting A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Graft vs. Host Disease
Interventions: Drug: Obinutuzumab;   Drug: Placebo
10 Completed Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Rituximab
11 Completed Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
Conditions: Hodgkin's Disease;   Breast Cancer
Intervention: Drug: Tamoxifen
12 Not yet recruiting Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Condition: Bone Cancer
Interventions: Drug: Stereotactic Body Radiation Therapy (SBRT);   Device: Stereotactic Linear Accelerator
13 Active, not recruiting
Has Results
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Condition: Graft Versus Host Disease
Intervention: Drug: Interleukin-2
14 Completed
Has Results
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: bortezomib;   Drug: Prednisone
15 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
16 Completed
Has Results
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Condition: Hematologic Malignancies
Interventions: Drug: Bortezomib (Velcade);   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: blood stem cell transplantation
17 Active, not recruiting
Has Results
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Interleukin-2
18 Terminated
Has Results
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
Condition: Graft-vs-Host Disease
Interventions: Drug: Sirolimus;   Drug: Mycophenolate mofetil;   Drug: Bortezomib
19 Completed Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
Conditions: Graft Versus Host Disease;   Hematologic Malignancies
Interventions: Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Stem Cell Transplantation
20 Terminated
Has Results
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Alefacept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.